SecBot SecBot
6-K ·Filed May 12, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 3/10
Horizonmonths Processed6mo ago SEC0001171843-26-003279
Notable filing: 6-K
Actionable Insight • Neutral

Monitor the EHA 2026 poster presentation on June 13 for data quality and any partnership discussions. The clinical trial application timeline (H2 2026) is the next major catalyst. No immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.17
T+0 close · May 12, 2026 · via day close
Latest settled
−28.18%
T+60 · $3.00
Vs SPY
−32.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $4.17entry
  2. T+1 · 6mo ago −0.24%α −0.82% · $4.16
  3. T+5 · 6mo ago −1.92%α −2.00% · $4.09
  4. T+20 · 5mo ago −9.11%α −7.39% · $3.79
  5. T+60 · 3mo ago −28.18%α −32.56% · $3.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced it will present preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine, at the EHA 2026 Congress in June. The data is preclinical and the company plans to submit a clinical trial application in H2 2026. This is a routine pipeline update with no financial data or near-term catalyst.

Key Facts

  • Evaxion to present functional characterization data for EVX-04 at EHA 2026 Congress on June 13, 2026
  • EVX-04 is an off-the-shelf therapeutic vaccine targeting acute myeloid leukemia (AML)
  • Preclinical data shows EVX-04 prevents tumor growth in preclinical models
  • Company plans to submit a clinical trial application in the second half of 2026
  • No financial data, revenue, or guidance provided in the filing

Financial Impact

No financial impact disclosed; preclinical milestone with no revenue or cost figures

Risk Factors

  • Preclinical data may not translate to clinical success
  • Company requires additional capital to fund clinical development
  • AML vaccine market is competitive with established therapies

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-003279
Document: f6k_051226.htm0001171843-26-003279
Document: 0001171843-26-003279-index-headers.html0001171843-26-003279
Document: 0001171843-26-003279-index.html0001171843-26-003279
Document: 0001171843-26-003279.txt0001171843-26-003279

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026